menu
    • menu
    [{"orgOrder":0,"company":"K36 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KTX-1001","moa":"Methyltransferase","graph1":"Oncology","graph2":"Phase I","graph3":"K36 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"K36 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"K36 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"K36 Therapeutics","sponsor":"Nextech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"KTX-1001","moa":"Methyltransferase","graph1":"Oncology","graph2":"Phase I","graph3":"K36 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"K36 Therapeutics \/ Nextech","highestDevelopmentStatusID":"6","companyTruncated":"K36 Therapeutics \/ Nextech"}]

    Find Clinical Drug Pipeline Developments & Deals by K36 Therapeutics

    Menu

    K36 Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            K36 Therapeutics

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            K36 Therapeutics

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KTX-1001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Nextech

                            Deal Size : $70.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First...

                            Details : The funds will support the ongoing Phase 1 of KTX-1001, an oral small molecule, clinical studies of KTX-1001 in combination with existing standard-of-care agents in multiple myeloma and the expansion of KTX-1001 into additional hematological and solid tu...

                            Product Name : KTX-1001

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 28, 2023

                            Lead Product(s) : KTX-1001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Nextech

                            Deal Size : $70.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            K36 Therapeutics

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed

                            K36 Therapeutics

                            U.S.A arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KTX-1001

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            K36 Therapeutics Announces FDA Clearance of Investigational New Drug Application and Formation of Clinical Adv...

                            Details : KTX-1001 is a first-in-class, potent, and selective inhibitor of multiple myeloma SET domain (MMSET) for the treatment of patients with relapsed and refractory multiple myeloma.

                            Product Name : KTX-1001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 23, 2022

                            Lead Product(s) : KTX-1001

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth